Geron (GERN) EBT (2010 - 2026)
Geron (GERN) posted EBT of -$3.6 million for Q1 2026, up 87.61% sequentially from -$28.8 million in Q4 2025, and up 81.94% YoY from -$2.0 million in Q1 2025.
Geron (GERN) EBT (2010 - 2026) Analysis & Trends
Geron has reported EBT for 17 years, with the latest figure at -$3.6 million in Q1 2026.
- Quarterly EBT rose 81.94% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.9 million (up 51.16% YoY) and the FY2025 annual result came in at -$495.1 million, up 15.23% from the prior year.
- EBT advanced to -$3.6 million in Q1 2026 per GERN's latest filing, from -$28.8 million in the prior quarter.
- Over five years, EBT peaked at -$3.6 million in Q1 2026 and troughed at -$67.3 million in Q2 2024.
- A 5-year average of -$34.4 million and a median of -$30.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2023 and 2026: EBT tumbled 68.39% in 2023, then soared 81.94% in 2026.
- Over 5 years, EBT stood at -$41.0 million in 2022, then decreased by 23.73% to -$50.7 million in 2023, then surged by 53.48% to -$23.6 million in 2024, then retreated by 22.02% to -$28.8 million in 2025, then soared by 87.61% to -$3.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$3.6 million, -$28.8 million, and -$18.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Geron | 1.04 Mn | -299.81 Mn | - | -16.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.67 Mn |
| Mar 31, 2026 | -3.57 Mn |
| Dec 31, 2025 | -28.79 Mn |
| Sep 30, 2025 | -18.27 Mn |
| Jun 30, 2025 | -16.31 Mn |
| Mar 31, 2025 | -19.75 Mn |
| Dec 31, 2024 | -23.60 Mn |
| Sep 30, 2024 | -26.38 Mn |
| Jun 30, 2024 | -67.32 Mn |
| Mar 31, 2024 | -55.33 Mn |
| Dec 31, 2023 | -50.72 Mn |
| Sep 30, 2023 | -44.71 Mn |
| Jun 30, 2023 | -49.22 Mn |
| Mar 31, 2023 | -38.16 Mn |
| Dec 31, 2022 | -40.99 Mn |
| Sep 30, 2022 | -40.91 Mn |
| Jun 30, 2022 | -29.23 Mn |
| Mar 31, 2022 | -30.69 Mn |
| Dec 31, 2021 | -30.98 Mn |
| Sep 30, 2021 | -26.62 Mn |